A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

A panelist discusses how given PODIUM-303's benefits across all subgroups, the primary patient population that should receive chemotherapy alone rather than the combination with retifanlimab would be ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...

This new article publication from Acta Pharmaceutica Sinica B, discusses targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by ...

US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer ...

First trial participant treated with PTM-101, an investigational thin film formulation of paclitaxel placed directly over the tumor for continuous localized ...

Disease-free and overall survival were comparable between paclitaxel- and cisplatin-based heated chemotherapy regimens in ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Paclitaxel (PTX) has emerged as one of the first-line drug candidates in cancer therapy due to its potency and profound anticancer potential. Derived from a rich natural source, it stands out as a ...

While chemotherapy can be lifesaving, it also damages DNA and leads to cognitive issues known as "chemo brain." These effects resemble the memory and learning problems seen in older adults, prompting ...